Finding new drugs to slow down Alzheimer's disease progression.
Official title: Discovery and development of OGG1 activators as precision drugs for modification of Alzheimer's disease progression.
Funded at Luciole Pharmaceuticals, INC. · NIH-10930103 · Data updated 2026-11-12
This study is looking for ways to help your body repair damage to the DNA in your cells, which can be a big part of Alzheimer's disease, with the hope of slowing down the disease's progression and improving your overall brain health.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Luciole Pharmaceuticals, INC. NIH-funded |
| Lab location | 1 site (Sherborn, UNITED STATES) |
| Project start | September 18, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $198,117 |
| NIH project number | 5R43AG084412-02 |
| Project ID | NIH-10930103 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults aged 21 and older who are diagnosed with Alzheimer's disease.
✕Less likely to help
Patients with other forms of dementia or those under 21 years old may not benefit from this research.
What this research studies
This research focuses on developing activators for the OGG1 enzyme, which plays a crucial role in repairing oxidative damage to mitochondrial DNA, a key factor in Alzheimer's disease progression. By enhancing the body's ability to repair this damage, the research aims to address the underlying causes of Alzheimer's rather than just alleviating symptoms. The approach involves understanding the mechanisms of oxidative stress and mitochondrial dysfunction in Alzheimer's patients and testing new compounds that could improve mitochondrial health. Patients may be monitored for changes in disease progression through innovative biomarkers.
Why it matters
Potential benefit: If successful, this research could lead to new precision drugs that significantly slow the progression of Alzheimer's disease.
How similar studies have gone: While there have been various approaches to treating Alzheimer's, targeting base excision repair of oxidative damage is a novel and untested strategy.
Where this research is happening
-
Luciole Pharmaceuticals, INC.
Sherborn, United States Active
Researchers
- Principal investigator: Rumsey, William L — Luciole Pharmaceuticals, INC.
- Study coordinator: Rumsey, William L
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.